Published in Am J Prev Med on February 01, 2006
Diabetes health disparities: a systematic review of health care interventions. Med Care Res Rev (2007) 3.95
Socioeconomic and ethnic disparities in cardiovascular risk in the United States, 2001-2006. Ann Epidemiol (2010) 2.07
Cardiovascular health disparities: a systematic review of health care interventions. Med Care Res Rev (2007) 1.83
Use of community-based participatory research to disseminate baseline results from a cardiovascular disease randomized community trial for Mexican Americans living in a U.S.-Mexico border community. Educ Health (Abingdon) (2009) 1.64
Hypertension and diabetes prevalence among U.S. Hispanics by country of origin: the National Health Interview Survey 2000-2005. J Gen Intern Med (2010) 1.43
Cost sharing and the initiation of drug therapy for the chronically ill. Arch Intern Med (2009) 1.41
Changes in racial/ethnic disparities in the prevalence of Type 2 diabetes by obesity level among US adults. Ethn Health (2009) 1.32
Changing trends in the prevalence and disparities of obesity and other cardiovascular disease risk factors in three racial/ethnic groups of USA adults. Adv Prev Med (2012) 1.30
Behavioral strategies for cardiovascular risk reduction in diverse and underserved racial/ethnic groups. Circulation (2012) 1.19
Mexican American trial of community health workers: a randomized controlled trial of a community health worker intervention for Mexican Americans with type 2 diabetes mellitus. Am J Public Health (2013) 1.12
Effectiveness of the Pasos Adelante chronic disease prevention and control program in a US-Mexico border community, 2005-2008. Prev Chronic Dis (2011) 1.06
Predictors of hypertension awareness, treatment, and control among Mexican American women and men. J Gen Intern Med (2009) 0.98
Physical disability trajectories in older Americans with and without diabetes: the role of age, gender, race or ethnicity, and education. Gerontologist (2010) 0.98
Gender and ethnic differences in the prevalence of type 2 diabetes among Asian subgroups in California. J Diabetes Complications (2013) 0.96
Immigration disparities in cardiovascular disease risk factor awareness. J Immigr Minor Health (2012) 0.90
Adverse vascular risk is related to cognitive decline in older adults. J Alzheimers Dis (2015) 0.87
Diabetic nephropathy among Mexican Americans. Clin Nephrol (2012) 0.86
Does the Prevalence of Dyslipidemias Differ between Newfoundland and the Rest of Canada? Findings from the Electronic Medical Records of the Canadian Primary Care Sentinel Surveillance Network. Front Cardiovasc Med (2015) 0.84
Diabetes-related change in physical disability from midlife to older adulthood: evidence from 1996-2003 Survey of Health and Living Status of the Elderly in Taiwan. Diabetes Res Clin Pract (2010) 0.84
Emotional and cognitive health correlates of leisure activities in older Latino and Caucasian women. Psychol Health Med (2011) 0.81
Circulating level of hepatocyte growth factor predicts incidence of type 2 diabetes mellitus: The Multi-Ethnic Study of Atherosclerosis (MESA). Metabolism (2015) 0.80
Pushing the envelope for cultural appropriateness: does evidence support cultural tailoring in type 2 diabetes interventions for Mexican American adults? Diabetes Educ (2011) 0.79
The prevalence of hypertension in older Mexicans and Mexican Americans. Ethn Dis (2008) 0.79
Access to care as a predictor of patients' knowledge of cardiovascular diseases. J Natl Med Assoc (2007) 0.79
The relationship of social support with treatment adherence and weight loss in Latinos with type 2 diabetes. Obesity (Silver Spring) (2016) 0.76
The Impact of Neighborhood Socioeconomic Position on Prevalence of Diabetes and Prediabetes in Older Latinos: The Sacramento Area Latino Study on Aging. Hisp Health Care Int (2015) 0.75
Socio-Economic Differences in the Association between Self-Reported and Clinically Present Diabetes and Hypertension: Secondary Analysis of a Population-Based Cross-Sectional Study. PLoS One (2015) 0.75
Do gender and race/ethnicity influence acute myocardial infarction quality of care in a hospital with a large Hispanic patient and provider representation? Cardiol Res Pract (2013) 0.75
Racial disparities in hypertension prevalence, awareness, and management. Arch Intern Med (2005) 5.09
Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature (2002) 5.02
Value of noninvasive hemodynamics to achieve blood pressure control in hypertensive subjects. Hypertension (2006) 2.31
Prevalence, awareness, and management of hypertension, dyslipidemia, and diabetes among United States adults aged 65 and older. J Gerontol A Biol Sci Med Sci (2009) 2.26
Predominance of AT(1) blockade over mas-mediated angiotensin-(1-7) mechanisms in the regulation of blood pressure and renin-angiotensin system in mRen2.Lewis rats. Am J Hypertens (2013) 2.11
Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension (2004) 1.96
Angiotensin II AT1 receptors regulate ACE2 and angiotensin-(1-7) expression in the aorta of spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol (2005) 1.92
Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats. Exp Physiol (2005) 1.85
ACE2 and ANG-(1-7) in the rat uterus during early and late gestation. Am J Physiol Regul Integr Comp Physiol (2007) 1.85
Adherence with pharmacotherapy for type 2 diabetes: a retrospective cohort study of adults with employer-sponsored health insurance. Clin Ther (2005) 1.84
Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor. Am J Physiol Heart Circ Physiol (2005) 1.81
Angiotensin metabolism in renal proximal tubules, urine, and serum of sheep: evidence for ACE2-dependent processing of angiotensin II. Am J Physiol Renal Physiol (2006) 1.61
Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin II-dependent hypertension. Hypertension (2009) 1.52
Differential expression of nuclear AT1 receptors and angiotensin II within the kidney of the male congenic mRen2. Lewis rat. Am J Physiol Renal Physiol (2006) 1.48
Impaired heart rate baroreflex in older rats: role of endogenous angiotensin-(1-7) at the nucleus tractus solitarii. Hypertension (2005) 1.45
Sex differences in circulating and renal angiotensins of hypertensive mRen(2). Lewis but not normotensive Lewis rats. Am J Physiol Heart Circ Physiol (2008) 1.41
Distinct roles for ANG II and ANG-(1-7) in the regulation of angiotensin-converting enzyme 2 in rat astrocytes. Am J Physiol Cell Physiol (2005) 1.40
Angiotensin II-induced skeletal muscle insulin resistance mediated by NF-kappaB activation via NADPH oxidase. Am J Physiol Endocrinol Metab (2007) 1.36
The impact of obesity on work limitations and cardiovascular risk factors in the U.S. workforce. J Occup Environ Med (2004) 1.34
Angiotensin-(1-12) is an alternate substrate for angiotensin peptide production in the heart. Am J Physiol Heart Circ Physiol (2008) 1.34
Abrogation of oxidative stress improves insulin sensitivity in the Ren-2 rat model of tissue angiotensin II overexpression. Am J Physiol Endocrinol Metab (2004) 1.33
NADPH oxidase contributes to vascular inflammation, insulin resistance, and remodeling in the transgenic (mRen2) rat. Hypertension (2007) 1.32
Estrogen or the AT1 antagonist olmesartan reverses the development of profound hypertension in the congenic mRen2. Lewis rat. Hypertension (2003) 1.32
Angiotensin-(1-7) in normal and preeclamptic pregnancy. Endocrine (2002) 1.30
Angiotensin-(1-7) inhibits growth of human lung adenocarcinoma xenografts in nude mice through a reduction in cyclooxygenase-2. Cancer Res (2007) 1.28
Injections of angiotensin-converting enzyme 2 inhibitor MLN4760 into nucleus tractus solitarii reduce baroreceptor reflex sensitivity for heart rate control in rats. Exp Physiol (2008) 1.24
Renin inhibition attenuates insulin resistance, oxidative stress, and pancreatic remodeling in the transgenic Ren2 rat. Endocrinology (2008) 1.21
Localization of the novel angiotensin peptide, angiotensin-(1-12), in heart and kidney of hypertensive and normotensive rats. Am J Physiol Heart Circ Physiol (2008) 1.20
MAP kinase/phosphatase pathway mediates the regulation of ACE2 by angiotensin peptides. Am J Physiol Cell Physiol (2008) 1.20
Regulation of ACE2 in cardiac myocytes and fibroblasts. Am J Physiol Heart Circ Physiol (2008) 1.20
Angiotensin-(1-7) and baroreflex function in nucleus tractus solitarii of (mRen2)27 transgenic rats. J Cardiovasc Pharmacol (2008) 1.20
Chymase-dependent generation of angiotensin II from angiotensin-(1-12) in human atrial tissue. PLoS One (2011) 1.17
Effect of renin inhibition and AT1R blockade on myocardial remodeling in the transgenic Ren2 rat. Am J Physiol Endocrinol Metab (2008) 1.15
Renin-angiotensin system expression in rat bone marrow haematopoietic and stromal cells. Br J Haematol (2004) 1.15
Modulation of reflex function by endogenous angiotensins in older transgenic rats with low glial angiotensinogen. Hypertension (2008) 1.12
Activation of local chorionic villi angiotensin II levels but not angiotensin (1-7) in preeclampsia. Hypertension (2008) 1.10
Cardiac angiotensin-(1-7) in ischemic cardiomyopathy. Circulation (2003) 1.09
Angiotensin-(1-7): pharmacology and new perspectives in cardiovascular treatments. Cardiovasc Drug Rev (2007) 1.08
Cardiac kallikrein-kinin system is upregulated in chronic volume overload and mediates an inflammatory induced collagen loss. PLoS One (2012) 1.08
Angiotensin II-induced non-alcoholic fatty liver disease is mediated by oxidative stress in transgenic TG(mRen2)27(Ren2) rats. J Hepatol (2008) 1.06
Growth, metabolism, and blood pressure disturbances during aging in transgenic rats with altered brain renin-angiotensin systems. Physiol Genomics (2005) 1.06
Novel aspects of the renal renin-angiotensin system: angiotensin-(1-7), ACE2 and blood pressure regulation. Contrib Nephrol (2004) 1.06
Effect of angiotensin II blockade on a new congenic model of hypertension derived from transgenic Ren-2 rats. Am J Physiol Heart Circ Physiol (2006) 1.05
Baroreceptor reflex regulation in anesthetized transgenic rats with low glia-derived angiotensinogen. Am J Physiol Heart Circ Physiol (2006) 1.05
Mineralocorticoid receptor antagonism attenuates glomerular filtration barrier remodeling in the transgenic Ren2 rat. Am J Physiol Renal Physiol (2009) 1.04
Primary role of angiotensin-converting enzyme-2 in cardiac production of angiotensin-(1-7) in transgenic Ren-2 hypertensive rats. Am J Physiol Heart Circ Physiol (2007) 1.04
Allelic variants of the human scavenger receptor class B type 1 and paraoxonase 1 on coronary heart disease: genotype-phenotype correlations. Arterioscler Thromb Vasc Biol (2005) 1.04
Angiotensin-(1-12) requires angiotensin converting enzyme and AT1 receptors for cardiovascular actions within the solitary tract nucleus. Am J Physiol Heart Circ Physiol (2010) 1.03
Angiotensin II activation of mTOR results in tubulointerstitial fibrosis through loss of N-cadherin. Am J Nephrol (2011) 1.03
Nebivolol reduces proteinuria and renal NADPH oxidase-generated reactive oxygen species in the transgenic Ren2 rat. Am J Nephrol (2009) 1.02
Enhanced renal immunocytochemical expression of ANG-(1-7) and ACE2 during pregnancy. Hypertension (2003) 1.01
Chronic immunoneutralization of brain angiotensin-(1-12) lowers blood pressure in transgenic (mRen2)27 hypertensive rats. Am J Physiol Regul Integr Comp Physiol (2009) 1.01
Aging and the brain renin-angiotensin system: insights from studies in transgenic rats. Cleve Clin J Med (2007) 1.00
New angiotensins. J Mol Med (Berl) (2008) 1.00
Uptake and metabolism of the novel peptide angiotensin-(1-12) by neonatal cardiac myocytes. PLoS One (2011) 1.00
Distinct roles for angiotensin-converting enzyme 2 and carboxypeptidase A in the processing of angiotensins within the murine heart. Exp Physiol (2008) 1.00
Mineralocorticoid receptor antagonism attenuates vascular apoptosis and injury via rescuing protein kinase B activation. Hypertension (2008) 0.99
Rats with low brain angiotensinogen do not exhibit insulin resistance during early aging. Endocrine (2006) 0.97
Inhibition of angiotensin-converting enzyme 2 exacerbates cardiac hypertrophy and fibrosis in Ren-2 hypertensive rats. Am J Hypertens (2010) 0.95
Sex differences in baroreflex sensitivity, heart rate variability, and end organ damage in the TGR(mRen2)27 rat. Am J Physiol Heart Circ Physiol (2011) 0.95
Characterization of the cardiac renin angiotensin system in oophorectomized and estrogen-replete mRen2.Lewis rats. PLoS One (2013) 0.95
Addressing the global cardiovascular risk of hypertension, dyslipidemia, and insulin resistance in the southeastern United States. Am J Med Sci (2005) 0.94
Angiotensin receptors contribute to blood pressure homeostasis in salt-depleted SHR. Am J Physiol Regul Integr Comp Physiol (2003) 0.94
Beneficial versus harmful effects of Angiotensin (1-7) on impulse propagation and cardiac arrhythmias in the failing heart. J Renin Angiotensin Aldosterone Syst (2007) 0.93
Role of the vasodilator peptide angiotensin-(1-7) in cardiovascular drug therapy. Vasc Health Risk Manag (2007) 0.93
Angiotensin I, angiotensin II and their biologically active peptides. J Hypertens (2002) 0.93
ACE2: angiotensin II/angiotensin-(1-7) balance in cardiac and renal injury. Curr Hypertens Rep (2014) 0.92
Mechanisms linking angiotensin II and atherogenesis. Curr Opin Lipidol (2002) 0.92
Does angiotensin-(1-7) contribute to cardiac adaptation and preservation of endothelial function in heart failure? Circulation (2002) 0.91
Chymase mediates angiotensin-(1-12) metabolism in normal human hearts. J Am Soc Hypertens (2013) 0.90
Salt-induced renal injury in spontaneously hypertensive rats: effects of nebivolol. Am J Nephrol (2010) 0.89
Comparative effect of direct renin inhibition and AT1R blockade on glomerular filtration barrier injury in the transgenic Ren2 rat. Am J Physiol Renal Physiol (2009) 0.89
Rosuvastatin ameliorates the development of pulmonary arterial hypertension in the transgenic (mRen2)27 rat. Am J Physiol Heart Circ Physiol (2009) 0.88
Combination of direct renin inhibition with angiotensin type 1 receptor blockade improves aldosterone but does not improve kidney injury in the transgenic Ren2 rat. Regul Pept (2012) 0.87
The protective effects of angiotensin II blockade with olmesartan medoxomil on resistance vessel remodeling (The VIOS study): rationale and baseline characteristics. Am J Cardiovasc Drugs (2006) 0.87
Nebivolol improves diastolic dysfunction and myocardial remodeling through reductions in oxidative stress in the transgenic (mRen2) rat. Am J Physiol Heart Circ Physiol (2012) 0.87
Pregnancy enhances the angiotensin (Ang)-(1-7) vasodilator response in mesenteric arteries and increases the renal concentration and urinary excretion of Ang-(1-7). Endocrinology (2003) 0.87
Healthcare spending among community-dwelling adults with schizophrenia. Am J Manag Care (2005) 0.87
Blood pressure-independent attenuation of cardiac hypertrophy by AT(1)R-AS gene therapy. Hypertension (2002) 0.87
Concern Oxidative stress-mediated mitochondrial dysfunction contributes to angiotensin II-induced nonalcoholic fatty liver disease in transgenic Ren2 rats. Am J Pathol (2009) 0.86
Hemodynamic and hormonal changes to dual renin-angiotensin system inhibition in experimental hypertension. Hypertension (2012) 0.86
Nebivolol reduces cardiac angiotensin II, associated oxidative stress and fibrosis but not arterial pressure in salt-loaded spontaneously hypertensive rats. J Hypertens (2012) 0.85
Restoration of the blood pressure circadian rhythm by direct renin inhibition and blockade of angiotensin II receptors in mRen2.Lewis hypertensive rats. Ther Adv Cardiovasc Dis (2012) 0.85
Olmesartan for the treatment of arterial hypertension. Future Cardiol (2008) 0.85
Racial and ethnic disparities in the prevalence and management of cardiovascular risk factors in the United States workforce. J Occup Environ Med (2007) 0.85
Divergent regulation of circulating and intrarenal renin-angiotensin systems in response to long-term blockade. Am J Nephrol (2005) 0.84
Role of blood pressure reduction in prevention of cardiac and vascular hypertrophy. Am J Hypertens (2005) 0.84
Angiotensin peptides modulate bradykinin levels in the interstitium of the dog heart in vivo. J Pharmacol Exp Ther (2002) 0.84
Characterization of angiotensin-(1-7) receptor subtype in mesenteric arteries. Peptides (2003) 0.84
Reversal of vascular hypertrophy in hypertensive patients through blockade of angiotensin II receptors. J Am Soc Hypertens (2010) 0.83
Angiotensin-(1-12): a chymase-mediated cellular angiotensin II substrate. Curr Hypertens Rep (2014) 0.83
Central depletion of angiotensinogen is associated with elevated AT1 receptors in the SFO and PVN. Neurotox Res (2004) 0.83
Reduced circulating levels of angiotensin-(1--7) in systemic sclerosis: a new pathway in the dysregulation of endothelial-dependent vascular tone control. Ann Rheum Dis (2007) 0.83
Nebivolol improves insulin sensitivity in the TGR(Ren2)27 rat. Metabolism (2011) 0.83
Decreased cardiac Ang-(1-7) is associated with salt-induced cardiac remodeling and dysfunction. Ther Adv Cardiovasc Dis (2009) 0.83
Increased expression of angiotensin converting enzyme 2 in conjunction with reduction of neointima by angiotensin II type 1 receptor blockade. Hypertens Res (2008) 0.83
Renin inhibition and AT(1)R blockade improve metabolic signaling, oxidant stress and myocardial tissue remodeling. Metabolism (2013) 0.82
Self-reported influences of hopelessness, health literacy, lifestyle action, and patient inertia on blood pressure control in a hypertensive emergency department population. Am J Med Sci (2009) 0.82
Noninvasive hemodynamic profiles in hypertensive subjects. Am J Hypertens (2005) 0.82